Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Nxstage Medical, Inc. (NXTM) Files Form 4 Insider Selling : Joseph E Jr Turk ... - Insider Trading Report |
 |
 |
|
Nxstage Medical, Inc. (NXTM): Joseph E Jr Turk , President of Nxstage Medical, Inc. sold 2,839 shares on Jun 10, 2015. The Insider selling transaction was disclosed on Jun 10, 2015 to the Securities and Exchange Commission. The shares were sold at $16.00 per share for a total value of $45,424.00. According to the SEC Form-4 filing, the Company has disclosed other insider buying and selling activities, The Securities and Exchange Commission has divulged that Turk Joseph E Jr, (President) of Nxstage Medical, Inc., had unloaded 2,000 shares at an average price of $16.64 in a transaction dated on May 26, 2015. The total value of the transaction was worth $33,280. The company shares have rallied 14.61% from its one year high price. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $17.32 and the 200 day moving avarge is recorded at $17.63. S&P 500 has rallied 7.25% during the last 52-weeks. 12.08% of the shares are held by the company Insiders, 91.2% of the shares are held by the institutions. Company shares has an average 3 month share volume of 486,912 and an average 10 day volume is recorded to be 459,425 Shares of NxStage Medical, Inc. (NASDAQ:NXTM) ended Monday session in red amid volatile trading. The shares closed down 0.15 points or 0.94% at $15.85 with 375,762 shares getting traded. Post opening the session at $15.99, the shares hit an intraday low of $15.76 and an intraday high of $16.11 and the price vacillated in this range throughout the day. The company has a market cap of $1,002 million and the number of outstanding shares has been calculated to be 63,238,000 shares. The 52-week high of NxStage Medical, Inc. (NASDAQ:NXTM) is $19.63 and the 52-week low is $11.5. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market. |
